Two top influencers with opposing viewpoints debate.
A lively and informative 3-part debate from Endo Sessions 2017, Chicago, 02 April 2017 (audio, video and slides available, gratis)
The Diabetes Dilemma: How to Treat Type 2 Diabetes?
The New Drugs: Are We Benefitting Anyone Other Than Pharma?
David M. Nathan, MD
Harvard Medical School,Massachusetts General Hospital
New Drugs for Diabetes: True Innovation with Real Patient Benefits
Daniel J Drucker, MD
Mt. Sinai Hospital, Toronto, ON
Debate Rebuttals and Moderated Q&A
Gordon C. Weir, MD
Joslin Diabetes Center/Harvard Medical School
insulin, metformin, SGLT-2 inhibitors, TZDs, sulfonylurias, DPP-4 inhibitors, GLP-agonists, insulin analogs, combinations, insulin resistance, monotherapy, polypharmacy, NPH, regular, Apidra, Novolog, potency, cost, affordability, effectiveness, pharma, side effects, adverse effects, DCCT, UKPDS, DCCT-EDIC, ACCORD, ADVANCE, VADT, Kumamoto, liraglutide, semaglutide, empaglifozin, MACE, CVD, biguanides, GLP-1 agonists, basal, rapid-acting, amylinhmimetics, Symlin, UTI, URI, yeast infection, pramlintide, hypoglycemia, lacticacidosis, pancreatitis, DKA, Invokana, risks versus benefits, patent protection, directc advertising, me-too drugs, bladder cancer, black box warnings, pharma, generic, GRADE, comparative effectiveness, personalized medicine, demagraphics, individualized therapy, hypoglycemia, bias, treat-to-target, high risk groups, elderly, post-MI, primary care, endocrinology, step-wise approach, clinicsl inertia, FDA approval process, complications, polys, study flaws, confounding factors, placebo, absolute risk reduction, ethics, fda approval process,
Note: FDA Approval Process –
Silent MIs excluded from one study!